EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Real‐world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study

Ralf Gutzmer iD, Michael Weichenthal iD, Thomas Eigentler, Peter Mohr, Thomas Sickmann, Pia Dücker, Christoffer Gebhardt iD, Sebastian Haferkamp, Katharina C Kähler, Friedegund Meier, Claudia Pföhler, Anca Sindrilaru und 7 weitere

International Journal of Cancer · 01.08.2026 · 159 (3) · 683-698

DOI: 10.1002/ijc.70440 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, online erschienen am 15.03.2026. Verfasst von Ralf Gutzmer und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Johannes-Wesling-Klinikum Minden/Ruhr-University Bochum, Minden, Germany. Hauptthemen laut MEDLINE: Ipilimumab, Melanoma, Nivolumab, Brain Neoplasms. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prospective, German NICO study ( ClinicalTrials.gov identifier: NCT02990611) evaluated real‐world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone (any‐line) in patients with advanced melanoma with/without melanoma brain metastasis (MBM). A total of 755 patients treated with nivolumab plus ipilimumab ( n = 486; median follow‐up, 46.8 months) or nivolumab alone ( n = 269; median follow‐up, 38.7 months) were enrolled. Baseline characteristics differed between the treatment groups, with the nivolumab plus ipilimumab group being younger and having poorer prognostic factors. At baseline, 221 patients (29.3%) had MBM, among whom 15 patients had symptomatic MBM based on dexamethasone use. In patients with/without MBM receiving first‐line nivolumab plus ipilimumab, objective response rates (ORRs) were 46.2% and 54.0%, respectively; 3‐year overall survival (OS) rates were 34.0% and 47.0%. In patients with/without MBM receiving first‐line nivolumab alone, ORRs were 61.5% and 55.1%, respectively; 3‐year OS rates were 42.7% and 47.8%. In a 3‐month landmark analysis, patients with MBM with a complete/partial response demonstrated 3‐year OS rates of 71.9% with nivolumab plus ipilimumab and 89.6% with nivolumab alone. Three‐year OS rates were 42.2% and 20.0% with asymptomatic and symptomatic MBM, respectively. There were no substantial differences in the rates of serious grade 3/4 treatment‐related adverse events between patients with/without MBM. HRQoL was stable. Results from this real‐world study show that a substantial proportion of patients with MBM derive long‐term benefit from nivolumab plus ipilimumab or nivolumab alone, particularly those with asymptomatic MBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IpilimumabMelanomaNivolumabBrain NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedProspective StudiesGermanyAdultAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

brain metastasisipilimumabmelanomanivolumaboverall survival

Substanzen

IpilimumabNivolumab

Autor:innen und Institutionen

  • Department of Dermatology, Johannes-Wesling-Klinikum Minden/Ruhr-University Bochum, Minden, Germany.
  • Department of Dermatology, Venereology and Allergology, Schleswig-Holstein University Hospital (UK-SH), Campus Kiel, Kiel, Germany.
  • Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Department of Dermatology, Elbe-Klinikum Buxtehude, Buxtehude, Germany.
  • Medical Department, Bristol Myers Squibb, Munich, Germany.
  • Department of Dermatology, Klinikum Dortmund, Dortmund, Germany.

ORCID-Profile: Ralf Gutzmer, Michael Weichenthal, Christoffer Gebhardt, Dirk Schadendorf

Förderung

  • Bristol-Myers Squibb

Zitieren

APA

Gutzmer, R., Weichenthal, M., Eigentler, T., Mohr, P., Sickmann, T., Dücker, P., Gebhardt, C., Haferkamp, S., Kähler, K. C., Meier, F., Pföhler, C., Sindrilaru, A., Terheyden, P., von Wasielewski, I., Ugurel, S., Ulrich, J., Utikal, J., Weishaupt, C., & Schadendorf, D. (2026). Real‐world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study. International Journal of Cancer, 159(3), 683-698. https://doi.org/10.1002/ijc.70440

Vancouver

Gutzmer R, Weichenthal M, Eigentler T, Mohr P, Sickmann T, Dücker P, et al. Real‐world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study. International Journal of Cancer. 2026;159(3):683-698. doi:10.1002/ijc.70440

BibTeX
@article{Gutzmer2026,
  author = {Gutzmer, Ralf and Weichenthal, Michael and Eigentler, Thomas and Mohr, Peter and Sickmann, Thomas and Dücker, Pia and Gebhardt, Christoffer and Haferkamp, Sebastian and Kähler, Katharina C and Meier, Friedegund and Pföhler, Claudia and Sindrilaru, Anca and Terheyden, Patrick and von Wasielewski, Imke and Ugurel, Selma and Ulrich, Jens and Utikal, Jochen and Weishaupt, Carsten and Schadendorf, Dirk},
  title = {Real‐world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {159},
  number = {3},
  pages = {683--698},
  doi = {10.1002/ijc.70440}
}
Kostenlos starten →